NASDAQ · Biotechnology

Karyopharm Therapeutics Inc. (KPTI) Stock

$7.60 +2.56% NASDAQ: KPTI Healthcare

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways.

Valuation

MetricValue
Price$7.60
Market Cap$172.24M
P/E Ratio-0.50
P/B Ratio-0.61
P/S Ratio1.11
EPS (TTM)$-17.93
52-Week High$10.99
52-Week Low$3.65
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE73.11%
ROA-148.36%
ROCE-596.61%
Gross Margin-62.33%
Operating Margin-62.33%
Net Margin-129.02%
Debt/Equity-0.87
Current Ratio1.12

Annual Financials (USD)

Metric20212022202320242025
Revenue$210.0M$157.0M$146.0M$145.0M$146.0M
Operating Profit$-98.0M$-142.0M$-130.0M$-119.0M$-91.0M
Net Profit$-124.0M$-165.0M$-143.0M$-76.0M$-196.0M
EPS$-24.75$-30.28$-18.79$-9.41$-17.93
Op Margin-46.8%-90.5%-88.7%-82.2%-62.1%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$305.0M$358.0M$240.0M$164.0M$108.0M
Total Liabilities$385.0M$375.0M$377.0M$350.0M$401.0M
Cash$190.0M$135.0M$52.0M$62.0M$61.0M
Borrowings$181.0M$179.0M$177.0M$195.0M$234.0M

Latest News

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) PR Newswire · Jul 1, 2026 Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update Simply Wall St. · Jun 25, 2026 Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress PR Newswire · Jun 14, 2026 Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress GlobeNewswire · Jun 14, 2026 How The Investment Story Is Evolving For Karyopharm Therapeutics (KPTI) Simply Wall St. · Jun 7, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-107.0M$-150.0M$-93.0M$-127.0M$-75.0M
Investing Cash Flow$136.0M$-104.0M$8.0M$95.0M$43.0M
Financing Cash Flow$4.0M$4.0M$0$-43.0M$0
Net Cash Flow$108.0M$-61.0M$-84.0M$10.0M$-2.0M
Free Cash Flow$-113.0M$-150.0M$-93.0M$-128.0M$-75.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA-2.03
FCF Yield-43.54%
Quick Ratio1.08
Interest Coverage-1.98
Return 1Y109.85%
Return 3Y-57.22%
Return 5Y-92.74%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ALGS $4.28 -1.04% -2.29 $26.45M 0.00%
BRNSBarinthus Biotherapeutics plc $0.67 +4.69% -0.41 — 0.00%
CVM $1.18 +0.00% -0.23 $8.11M 0.00%
FGENFibroGen, Inc. $9.07 -1.63% 0.22 $36.69M 0.00%
INMB $1.73 +6.79% -2.44 $45.99M 0.00%

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc. is a pharmaceutical company that has already brought products to market, focusing on identifying, advancing, and selling medications designed to disrupt nuclear export pathways. These drugs are primarily aimed at treating cancer and various other illnesses. The company's strategy involves researching, creating, and marketing innovative Selective Inhibitor of Nuclear Export (SINE) compounds, which operate by attaching to and deactivating the nuclear export protein XPO1. Their leading therapeutic, XPOVIO, holds approvals for several critical applications in adult patients: it is prescribed in combination with bortezomib and dexamethasone for multiple myeloma; alongside dexamethasone for those with heavily pretreated multiple myeloma; and as a standalone treatment for relapsed or refractory diffuse large B-cell lymphoma. Karyopharm has also established a licensing partnership with the Menarini Group, granting them rights to develop and market NEXPOVIO for human oncology indications across Europe (including the United Kingdom), Latin America, and other global regions. Furthermore, the company's oral SINE compounds are specifically engineered to promote the accumulation of various tumor suppressor and growth-regulating proteins within the cell nucleus. Established in 2008, Karyopharm Therapeutics Inc. maintains its principal offices in Newton, Massachusetts.

Karyopharm Therapeutics Inc. is led by CEO Richard A. Paulson, employs 279 people, headquartered in US, publicly traded since 2013.

Karyopharm Therapeutics Inc. (KPTI) stock trades at $7.60 with a market capitalization of $172.24M. The stock is valued at a price-to-earnings (P/E) ratio of -0.50, price-to-book of -0.61, price-to-sales of 1.11. Over the past 52 weeks the stock has ranged between $3.65 and $10.99, and currently trades 30.8% below its 52-week high.

On profitability, Karyopharm Therapeutics Inc. generates a return on equity (ROE) of 73.11% — well above the market average, a sign of a high-quality business, return on capital employed of -596.61%, an operating margin of -62.33%, a net profit margin of -129.02%.

Official website: www.karyopharm.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides